secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beyond Air, Inc. (XAIR)
CIK:        0001641631
Form:       8-K
Filed at:   2023-11-17T23:59:59+00:00
Accession:  0001493152-23-041878
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beyond Air Q2 net loss widens to $16.2M; guides FY2025 revenue $12-$16M
-----------------------------------------------------------------------

- Revenue $0.24M vs $0 prior year; net loss $16.2M ($0.51 loss per share) vs $12.0M ($0.40) prior year.
- Cash burn $16.5M ($10.1M ex one-time); cash & securities $43.9M as of Sept 30, 2023.
- FY2025 revenue guidance $12M-$16M; submitted PMA supplement for cardiac surgery; CE Mark expected H1 2024.
- Beyond Cancer presented positive first-in-human UNO data at SITC; VCAP trial underway, data mid-2024.
- Agreement with Getz Healthcare for Asia-Pacific; Vizient Innovative Technology contract awarded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/0001493152-23-041878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641631/000149315223041878/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer